and treatment response (4, 5) . Indeed, we previously demonstrated that several members of the ABCC/MRP subfamily are independently associated with survival in children with neuroblastoma, that the combined expression pattern of these transporters was a powerful predictor of clinical outcome, and remarkably, that these transporters influence neuroblastoma biology independently of their more established roles in chemotherapeutic drug efflux (6) .
ABC transporters are responsible for the transport of a variety of inflammatory mediators and lipids that have direct relevance to tumor progression in ovarian cancer (7) (8) (9) (10) and thus could contribute to clinical outcome and be potential therapeutic targets in this disease. Therefore we examined the expression of the entire ABC transporter gene family in a cohort of primary serous EOC specimens and investigated the relationship between gene expression and clinical outcome. This represents the largest study of its kind, with accurate determination of gene expression matched to comprehensive clinical follow-up data. Tables 1 and 2 , available online) (11, 12) . Sample size was determined to have 80% power to detect the difference between two equally sized groups, with a constant hazard ratio (HR) of 2 at a .05 two-sided significance level.
Methods

Patient Cohorts
Outcome and expression data generated by the Agilent microarray platform for 407 patients, most with high-grade, advancedstage disease were extracted from The Cancer Genome Atlas (TCGA) interface (http://tcga-data.nci.nih.gov/) (13) .
For the genome-wide association study (GWAS), 1430 case patients were available through 10 Ovarian Cancer Association Consortium sites, as described elsewhere (14) . Patient selection was limited to those receiving only paclitaxel and carboplatin as first-line chemotherapy (Supplementary Table 1 , available online).
The cohort for immunohistochemical analysis was comprised of 91 patients with serous EOC diagnosed between 1987 and 2007 and treated at Westmead Hospital, Sydney, Australia (Supplementary  Methods and Supplementary Tables 1 and 3, available online) .
Institutional review board approval was obtained by each cohort study, and this project was approved by the University of New South Wales Human Research Ethics Committee.
ABC Transporter Expression Analysis
RNA was prepared from tumor specimens using the RNeasy extraction kit (QIAGEN, Melbourne, Australia), reverse transcribed with Moloney Murine Leukemia Virus reverse-transcriptase (Life Technologies, Melbourne, Australia) as described (15, 16) and applied to custom-made Taqman low-density array cards (Applied Biosystems, Sydney, Australia) as described in the Supplementary Methods (available online). Details of tissue microarray sample preparation, staining, and analysis are presented in the Supplementary Methods (available online).
GWAS Analysis
We conducted a two-stage GWAS to identify germline single nucleotide polymorphisms (SNPs) associated with progression-free survival (PFS) and overall survival (OS) in serous EOC patients. We first examined the association between SNPs in ABCA1, ABCA5, ABCA6, ABCA8, and ABCA9 from 385 strictly selected samples to maximize detection of informative SNPs (discovery stage). We then expanded the analysis to a total of 1430 case patients from nine sites within the Ovarian Cancer Association Consortium and genotyped the leading SNP at each locus (except ABCA9 because no SNPs at this locus showed association) (replication stage).
Cell Culture and Transfection
Human ovarian cancer cell lines 27/87 (17), A2780 (T. Hamilton, Fox-Chase Cancer Center, Philadelphia, PA) and SKOV-3 (ATCC, Manassas, VA) were cultured in Roswell Park Memorial Institute (RPMI) medium containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA). The cell lines were authenticated by short tandem repeat (STR) DNA profiling in November 2011 (Cell ID System, Promega, Sydney, Australia). Lipofectamine 2000 reagent (Invitrogen) was used to deliver short interfering RNA (siRNA) targeted toward ABCA1 (5 nM, sense: 5′ GGAGAUGGUUAUACAAUAGUUUU) or siCONTROL nontargeting siRNA (Dharmacon, Lafayette, CO). Subsequent cell-based assays are described in the Supplementary Methods (available online).
Statistical Analyses
For real-time quantitative PCR (RT-qPCR) expression data, values were categorized high or low by the median value. Clinical outcome between groups was compared using Kaplan-Meier analysis followed by two-sided log-rank tests (SPSS version 22, IBM Software, Sydney, Australia). Treatment of TCGA data is detailed in the Supplementary Methods (available online). Cox proportional hazards modelling (SPSS) was used to generate hazards ratios and 95% confidence intervals (CIs). Assumption of proportionality for each covariable was checked by visual inspection of plots of log (-log(S(t))) over time. In analyses where associations between gene expression and outcome in the AOCS dataset were subsequently examined for cross-validation in TCGA, no multiple testing adjustment was used. For all other gene expression survival analyses, P values were derived after Bonferroni adjustment for multiple testing.
For cell-based assays, differences in phenotypic traits between groups were assessed by two-sided Student t tests, unless indicated otherwise. For comparisons involving more than two groups, oneway analysis of variance was performed, followed by pair-wise t tests with Bonferroni correction. Significance was assessed at the level of P less than .05.
results
ABC Transporter Gene Expression and Clinical Outcome in EOC
For the 143 tumors analyzed by RT-qPCR, the only genes whose high expression was associated with outcome belong to the ABCA subfamily, with expression of ABCA6, ABCA8, and ABCA9 associated with shorter PFS or OS (Table 1 ; Figure 1 , A-C). The effect of ABCA6 expression on PFS and ABCA6 and ABCA9 expression on OS remained statistically significant after adjustment for tumor stage and residual disease (Table 1 ). In contrast, low levels of the MRP/ ABCC subfamily member ABCC11 were associated with shorter PFS (Table 1; Figure 1D ). When these genes were examined in an independent dataset available through TCGA, high levels of ABCA6 and ABCA8 were associated with reduced PFS or OS (Figure 1 , E and F; Supplementary Table 5 , available online), whereas high ABCA9 levels were associated with reduced PFS or OS in patients without macroscopic disease after surgery ( Figure 1G ; Supplementary Table 5 , available online). Each of these associations remained statistically significant in multivariable analysis of TCGA data (Supplementary Table 5 , available online). The association between low-level ABCC11 and shorter PFS was not validated in this cohort.
The extent of residual tumor remaining after surgery is a critical determinant of clinical outcome (Table 1) . To identify genes whose expression may be associated with progression in relatively favorable disease, analysis was carried out in AOCS patients with less than 1 cm of residual disease after surgery. In addition to ABCA6, ABCA8, and ABCA9, high expression of the cholesterol transporter, ABCA1, was statistically significantly associated with reduced OS in this group ( Figure 1H ; Table 1 ). Thus, the cumulative 5-year survival in patients expressing high levels of ABCA1 was 42.2%, compared with 68% for those expressing low levels of ABCA1 (log-rank P = .03). In contrast, low levels of ABCA5 expression were associated with shorter OS (P = .04) ( Figure 1I ; Table 1 ). High ABCA1 expression or low ABCA5 expression was also associated with reduced overall survival after adjustment for tumor stage (Supplementary Table 6 , available online). Validation in TCGA patients indicated that ABCA1 gene expression was associated with PFS and OS ( Figure 1J ; Supplementary Table 5 , available online), which remained unchanged upon adjustment for tumor stage and surgical debulking status (Supplementary Table 5 , available online). Multivariable Cox proportional hazards modelling was carried out in the subset of patients with less than 1 cm of residual disease to establish which of these ABCA genes might have prognostic value independently of each other and of tumor stage. Stepwise inclusion of each of the five genes in the model indicated that expression of ABCA1 and ABCA5, together with either ABCA8 or ABCA9, but not ABCA6, was independently associated with OS (Table 1) . 
Combined Expression of ABCA Genes and Clinical Outcome
Because expression of ABCA1, ABCA5, and either ABCA8 or ABCA9 was independently associated with survival when analyzed together in a multivariable model (Table 1) , these were considered to be the most robustly associated genes and to account for the majority of the predictive value. Thus, the effect of combined ABCA1, ABCA5, and either ABCA8 or ABCA9 gene expression on patient outcome was examined using a similar approach to that reported previously (6) . Tumors were divided according to eight possible combinations based on high or low expression of each set of three genes: for example, high expression of all three genes, high expression of two genes but low expression of the third, and so on. These eight combinations were compared with Kaplan-Meier curves, and clusters were recategorized into groups such that curves not statistically significantly (Figure 2A ). In contrast, group C included patients whose tumors had a favorable ABCA gene expression (ie, low ABCA1 and ABCA8 and high ABCA5 expression), and survival was longer (mean PFS in months = 30.9, 95% CI = 22.8 to 39.1, P = .004; mean OS in months = 52.8, 95% CI = 45.7 to 59.9, P = .002; vs group A) (Figure 2A) . The remaining case patients (group B) had intermediate survival, and the six subgroups did not differ statistically from one another. The combined expression status of ABCA1, ABCA5, and ABCA9 was similarly strongly predictive of outcome (mean PFS in months: group A = 12.9, 95% CI = 11.4 to 14.5, vs group C = 30.2, 95% CI = 21.9 to 38.5, P = .001; mean OS in months: group A = 33.2, 95% CI = 26.4 to 40.1, vs group C = 55.3, 95% CI = 49.8 to 60.8, P = .001) ( Figure 2B ). The combined expression levels of ABCA1/ABCA5/ABCA8 or ABCA1/ABCA5/ABCA9 were strongly associated with PFS and OS after adjusting for tumor stage and surgical debulking status ( Figure 2C ).
ABCA Transporter Gene SNPs and Clinical Outcome
From the discovery-stage GWAS (see Methods), we identified SNPs in ABCA1, ABCA5, ABCA6, and ABCA8 genes associated with PFS. The leading SNPs for each gene were genotyped on 1151 case patients in the replication stage. The overall associations combining case patients from both discovery and replication stages are presented in Table 2 . Of these, the ABCA5 variant, rs536009, strongly associated with both PFS and OS in serous ovarian cancer (HR = 1.33, 95% CI = 1.14 to 1.55, P = 3.1e−4 for PFS; HR death = 1.50, 95% CI = 1.26 to 1.79, P = 6.5e−6 for OS) ( Table 2 ; Supplementary Figure 1 , available online). Variant rs536009 would lead to a nonsynonymous amino acid change in ABCA5; however, because of strong linkage disequilibrium at this locus (Supplementary Figure 1C) , it is unclear whether this variant is causal.
ABCA Gene Expression in Molecular Subtypes of EOC Previously, Tothill (12) examined global gene expression profiles of 285
EOCs and found that the high-grade serous tumors (n = 215) clustered into four distinct groups based on similarities in their gene expression patterns, C1, C2, C4 and C5 (12) , and these were subsequently verified in TCGA data (18) . Expression data for ABCA genes in the Tothill dataset (12) indicated that ABCA1, ABCA6, and ABCA8 were each more highly expressed in C1 tumors than in the other classes, and a similar trend was seen for ABCA9 ( Figure 3A ; Supplementary Table 7 , available online). In the TCGA dataset (n = 380 high-grade serous tumors) similarly we observed that ABCA1, ABCA6, ABCA8, and ABCA9 were each more highly expressed in C1 tumors ( Figure 3B ; Supplementary Table 7 , available online). Molecular classes within TCGA data were of sufficient size for survival analysis. Within the C1 tumors, high expression of ABCA1 (mean OS in months: high ABCA1 = 35.9, 95% CI = 24.0 to 47.9; vs low ABCA1 = 61.6, 95% CI = 51.5 to 71.8; P = .003; P = .02 after Bonferroni correction) and high expression of ABCA6 (mean OS in months: high ABCA6 = 40.8, 95% CI = 32.7 to 48.9; vs low ABCA6 = 64.4, 95% CI = 52.6 to 76.2; P = .009; P = .045 after Bonferroni correction) were associated with reduced OS (Figure 3C ). Within C1 tumors, low expression of ABCA5 (mean OS in months: low ABCA5 = 36.8, 95% CI = 28.1 to 45.5; vs high ABCA5 = 60.8, 95% CI = 50.7 to 71.0; P = .02) was associated with reduced OS, but this was not statistically significant after Bonferroni correction (P = .09). The C1 tumor expression profile is characterized by markers of activated myofibroblasts, genes involved in extracellular matrix production, remodelling, and angiogenesis, and gene sets associated with poor prognosis in other studies (12, 19) . Therefore, we investigated ABCA gene expression in tumor vs infiltrating cells using data from Tothill and colleagues, who previously microdissected five C1 tumors and characterized the epithelial and stromal components by expression microarray (12) . Each of these five ABCA genes was expressed in both epithelial and stromal cells, although expression of ABCA6, ABCA8, and ABCA9 was biased toward the stromal cells (Supplementary Figure 2 , available online). Immunohistochemical detection of ABCA1 protein in serous EOC tumor sections confirmed strong staining for ABCA1 protein in tumor cells in cases with high ABCA1 mRNA levels by RT-qPCR, ( Figure 4A ). Furthermore, consistent with the observed associations between ABCA1 mRNA expression and outcome, in an independent cohort of 91 serous EOC tumors, high-level staining of ABCA1 protein was associated with poor PFS and OS (mean PFS in months: high ABCA1 = 21.9, 95% CI = 9.3 to 34.5, vs low ABCA1 = 50.0, 95% CI = 33.1-66.9, P = .04; mean OS in months: high ABCA1 = 36.0, 95% CI = 22.4 to 49.7, vs low ABCA1 = 63.8, 95% CI = 48.5 to 79.2, P = .04) ( Figure 4B ). 
ABCA1 Expression and Ovarian Cancer Cell Biology
In light of the high-level expression of ABCA1 in tumors of aggressive phenotype and predominant expression in tumor rather than stromal cells, we investigated the role of ABCA1 in ovarian cancer biology. The 27/87 cells depleted of ABCA1 by siRNA transfection displayed reduced colony-forming ability (mean colony number ± standard deviation [SD]: ABCA1 = 26.04 ± 7.86; Control = 60.04 ± 10.69; P = .002, Student t test) ( Figure 5A ), and similar observations were made with A2780 cells (mean percentage of control ± SD = 58.2 ± 7.76; P = .01, one-sample t test) ( Figure 5B ). Furthermore, in 27/87 cells, suppression of ABCA1 markedly reduced cell motility, as measured by closure of an artificial wound (mean area covered ± SD: ABCA1 = 60 480 ± 18 371; control = 138 500 ± 14 532; P = .004, Student t test) ( Figure 5C ). ABCA1 suppression also impaired migration of SKOV3 ovarian cancer cells (mean number of migrated cells ± SD: ABCA1 = 27.9 ± 12.10; control = 74.46 ± 13.87; P = .01, Student t test) ( Figure 5D ).
The importance of ABCA1 in cancer cell migration may be linked to its role in cholesterol homeostasis because cellular cholesterol and lipid content can influence morphology and mobility of the plasma membrane (20, 21) . In support of this possibility, when SKOV3 cells were exposed to subtoxic doses of the cholesterol-lowering drugs lovastatin or simvastatin, cell migratory ability was impaired (mean relative migration vs control ± SD: lovastatin = 0.64 ± 0.018, P < .001, Student t test; simvastatin = 0.65 ± .15, P = .06, Student t test) ( Figure 5E ). Thus, in addition to their known effects on cancer cell survival, statins may be useful as inhibitors of ovarian cancer cell migration.
Discussion
This is the first study to examine the entire ABC transporter gene superfamily in epithelial ovarian cancer in relation to clinical outcome. Expression of ABCA1, ABCA5, ABCA6, ABCA8, and ABCA9 were independently associated with outcome in two discrete (11) . B) Expression data for 380 serous ovarian cancers were obtained through The Cancer Genome Atlas (TCGA) and were generated by University of North Carolina using the Agilent 244K Custom Gene Expression Array. P values displayed in (A) and (B) are from one-way analysis of variance.
Horizontal lines indicate mean values. Asterisks indicate statistically significant differences in mean expression between C1 type and other types after Bonferroni correction: *P = .01; **P < .001; ***P < .05. C) Kaplan-Meier survival analysis of ABCA gene expression in C1 molecular subtype of serous ovarian cancer (TCGA expression array data). P values were calculated according to two-sided log-rank tests and Bonferroni adjustment for multiple testing. Gene expression was classified as high or low with respect to the upper decile (ABCA1, ABCA6, ABCA8, ABCA9) or lower quartile (ABCA5) of expression.
at Universitaet Erlangen-Nuernberg, Wirtschafts-und Sozialwissenschaftliche Z on August 3, 2016 http://jnci.oxfordjournals.org/ Downloaded from cohorts, and for ABCA1 this was further confirmed by immunohistochemical staining. Suppression of ABCA1 with siRNA altered the growth and migratory capacity of EOC cells, and we showed for the first time that statins inhibit ovarian cancer cell migration.
The A branch of the ABC superfamily comprises 12 functional transporters related by sequence homology and, at least for the most-well-studied members, by having discrete roles in cellular lipid trafficking (22) . ABCA1 is the most intensively studied, and its normal role in the maintenance of cellular cholesterol homeostasis through transfer of phospholipids and cholesterol to ApoA1, leading to the formation of high-density lipoprotein, is well established (23) . In cancer cells, the role of ABCA1 is unclear. An essential component of cellular membranes, cholesterol is rate-limiting for the rapid growth and division of tumor cells (24) and migration (20, 21) and can influence cell-cell signaling and drug sensitivity (25, 26) . Curiously, inhibitory effects of mitochondrial ABCA1 expression on colon cancer cells were observed in the context of Ras-driven disease (27) , although Ras mutation in ovarian cancer is predominantly associated with low-grade cases. Further experimentation should define the precise function for ABCA1 in high-grade EOC. Of relevance to EOC, omental adipose-derived lipids promote growth and metastases by providing energy to ovarian cancer cells (7) . Investigating the importance of ABCA transporters and lipid balance in this cycle could highlight new therapeutic targets.
Several cancers are associated with faulty cholesterol metabolism (28) , and a recent study of the Danish population linked statin use in cancer patients to reduced cancer-related mortality (29) . In EOC, a retrospective study suggested statins are associated with improved outcome and elevated serum low-density lipoprotein cholesterol levels with poor prognosis (30) . These findings concur with our observations that statin treatment or suppression of ABCA1 expression reduced EOC cell motility, and it would be prudent to examine association of metastatic disease with statin use in clinical studies.
The combined expression pattern of high ABCA1, low ABCA5, and high ABCA8 or ABCA9 identified tumors from patients with particularly poor outcome. A limitation of this finding is that, because of small patient numbers in the affected groups, we were unable to test for validation of this effect in the TCGA dataset. Further investigation of this relationship may require analysis of an independent cohort by RT-qPCR or similar quantitative measure.
Although the specific roles or substrates of ABCA5, ABCA6, ABCA8, and ABCA9 are largely unknown, their genes cluster on chromosome 17q24 (31, 32) , suggesting that they could be coregulated. However, ABCA5 expression was independently associated with outcome after adjustment for the expression of ABCA6, ABCA8, or ABCA9, and we found no relationship between the SNP genotype and any ABCA gene expression in the dataset from TCGA (data not shown). Nevertheless, further fine-mapping at the ABCA5 locus and investigation of the functional significance of rs536009 or other nearby SNPs (Supplementary Figure 1 , available online), some of which lie in potential enhancer sequences, may shed light on regulation of this region in EOC.
High-level expression of ABCA genes was associated with ovarian cancers displaying an active stromal component and poor outcome (12) , and ABCA1, ABCA5, and ABCA6 levels were also linked to outcome within this class. The development of many solid tumors, including those of the ovary, is facilitated by growth factors and other inflammatory mediators within the immediate tumor microenvironment (33) . High-level expression of ABCA genes could contribute to the reactive stroma. For example, among the phospholipids transferred to high-density lipoprotein by ABCA1 is the signaling lipid, sphingosine-1-phosphate (S1P). High-density lipoprotein-derived S1P appears to account for much of the angiogenic activity associated with ovarian follicular fluid (34) and also promotes ovarian cell migration (35) (36) (37) . Inhibition of S1P efflux could explain the observed inhibitory effects on cell growth and migration reported here after ABCA1 knockdown, and S1P efflux from tumor cells could also contribute to the desmoplastic tumor phenotype (38) (39) (40) . Testing these hypotheses should be a major focus of future work in this area.
Given the potential for pharmacological modulation using novel or existing agents, establishing the influence of ABCA family transporter activity on the tumor microenvironment, as well as on EOC cells themselves, should be a priority for future study. Identification of the key transported substances could also provide a tool for detection or monitoring of disease. 
